MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-03-2026
Aytu BioScience ROA Ratio 2011-2026 | AYTU
Annual ROA Ratio Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.92 | -13.42 | -12.49 | -79.04 | -21.94 | -8.91 | -78.14 | -48.38 | -150.07 | -115.76 | -42.37 | -46.43 | -592.8 | -471.85 | -599.01 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -8.91 | -599.01 | -152.77 |
Quarterly ROA Ratio Aytu BioScience
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.67 | 8.68 | 5.17 | 2.93 | -2.53 | -3.38 | -8.52 | -13.41 | -16.06 | -20.62 | -10.09 | -15.46 | -42.14 | -42.57 | -54.33 | -63.79 | -41.8 | -42.36 | -36.87 | -28.25 | -21.49 | -16.06 | -10.01 | -4.41 | -15.79 | -26.49 | -51.7 | -62.06 | -64.23 | -72.72 | -66.81 | -80.31 | -92.25 | -95.17 | -113.35 | -111.27 | -111.3 | -102.55 | -75.05 | -70.97 | -55.12 | -14576.99 | -52749.92 | -52731.7 | -53004.97 | -38699.86 | -1109.08 | -1701.78 | -1586.74 | -1523.54 | -1025.15 | -526.76 | -513.06 | -450.35 | -954.95 | -1459.55 | -1388.64 | -599.01 | -599.01 | -86.12 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.68 | -53004.97 | -3783.87 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burford Capital Limited
BUR
|
5.51 | $ 4.74 | 0.53 % | $ 761 M |  Britain |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 3.33 | 2.15 % | $ 335 M |  USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.07 | 0.49 % | $ 5.05 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 332.58 | -2.01 % | $ 43.6 B | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.8 | 4.97 % | $ 9.14 B |  Australia |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-27.33 | $ 7.51 | -14.07 % | $ 74.2 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
Esperion Therapeutics
ESPR
|
-4.87 | $ 2.11 | 2.77 % | $ 439 M | USA |
 |
Evogene Ltd.
EVGN
|
-39.9 | $ 0.82 | - | $ 27.9 M | Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
|
Forte Biosciences
FBRX
|
-83.81 | $ 32.35 | -0.2 % | $ 419 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
-1.99 | $ 28.99 | 0.36 % | $ 2.69 B |  Belgium |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 21.36 | -0.09 % | $ 998 M | USA |
 |
Genmab A/S
GMAB
|
22.5 | $ 29.02 | -0.14 % | $ 18.6 B |  Danmark |
 |
GT Biopharma
GTBP
|
-349.79 | $ 0.38 | -3.34 % | $ 2.1 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 99.43 | 1.03 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Hoth Therapeutics
HOTH
|
-164.0 | $ 0.68 | 4.58 % | $ 9.39 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Harmony Biosciences Holdings
HRMY
|
12.48 | $ 29.37 | 0.27 % | $ 1.69 B | USA |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
-2.45 | $ 7.61 | -1.55 % | $ 68.7 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.54 | -1.28 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.18 | 0.6 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.39 | -2.79 % | $ 3.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
|
Immatics N.V.
IMTX
|
1.73 | $ 10.9 | -0.46 % | $ 686 M | Germany |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Incyte Corporation
INCY
|
18.49 | $ 97.43 | -0.27 % | $ 19 B | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.46 | -1.49 % | $ 389 M | Britain |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Innate Pharma S.A.
IPHA
|
-19.74 | $ 1.71 | 4.91 % | $ 235 M | France |